Navelbine in the Treatment of Recurrent and Metastatic Breast Cancer.
- VernacularTitle:含诺维本方案治疗复发转移性乳腺癌疗效观察
- Author:
Yibo YAO
;
Bingchao DONG
- Publication Type:Journal Article
- Keywords:
NVB;
Breast Cancer;
Chemotherapy;
Bone Marrow Suppression
- From:
Journal of Medical Research
2006;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and adverse reactions of Navelbine(NVB)in the treatment of recurrent and metastatic breast cancer.Methods 34 patients with recurrent and metastatic breast cancer were treated with Navelbine in this clinical study,and 16 patients were treated by the NP(DDP+NVB)regimen,12 patients by the NA(ADM+NVB)regimen,6 patient by single-agent NVB.34 patients received above regimens for two cycles(3～4 week a cycle).Result The overall response rate(CR+PR)was 35.3%,clinical benefit rate(CR+PR+SD≥6 months)44.1%,disease contrrol rate(CP+PR+SD)58.8%,the median time to failure 3.4 months(range:0.7～11 months),the median time to progression(TTP)3 months(range:0.8～11 months),and the median duration of response(CP+PR)5 months(range:2～11 months).The main side effect of the therapies is bone marrow depression,and the grade Ⅲ～Ⅳ leucopenia is 35.3%.Conclusion Single Navelbine and Navelbine plus DDP(or ADM)are effective and well tolerated treatments in patients with recurrent and metastatic breast cancer.
